[go: up one dir, main page]

WO2018121743A1 - Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l'insuline - Google Patents

Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l'insuline Download PDF

Info

Publication number
WO2018121743A1
WO2018121743A1 PCT/CN2017/119889 CN2017119889W WO2018121743A1 WO 2018121743 A1 WO2018121743 A1 WO 2018121743A1 CN 2017119889 W CN2017119889 W CN 2017119889W WO 2018121743 A1 WO2018121743 A1 WO 2018121743A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
function
liver
seq
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/119889
Other languages
English (en)
Chinese (zh)
Inventor
彭长庚
温婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PENGEKIPHEN BIOTECH Ltd
Original Assignee
PENGEKIPHEN BIOTECH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PENGEKIPHEN BIOTECH Ltd filed Critical PENGEKIPHEN BIOTECH Ltd
Publication of WO2018121743A1 publication Critical patent/WO2018121743A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the present invention relates to the field of biomedicine, and in particular to the protection of liver and muscle by inhibiting the function of miR-96, and the prevention and/or treatment of nephropathy and its complications, and the decrease in total protein and/or albumin content in the blood.
  • the use of diseases and symptoms as well as insulin resistance also relates to the use of enhancing the function of miR-96 in enhancing lung function, and correspondingly to a method for enhancing the function of miR-96.
  • the present invention also relates to detection.
  • the amount of miR-96 expressed in the blood is used in predicting whether an individual has a risk of developing liver disease, kidney disease, and lung disease.
  • MicroRNAs are a class of non-coding RNA molecules (www.mirbase.org) that are 16-25 nt in length and can recognize and silence RNA expression and/or protein expression of target genes by complementary pairing with target genes. .
  • RISC RNA-induced silencing complex
  • the nucleotides from the second to the eighth position of the 5' end of the microRNA are called "core sequences". The complementary pairing of these seven nucleotides with the target gene is the key to recognition of the target gene.
  • microRNAs not only play an important role in development but also play an important regulatory role in adult tissues. Therefore, studying the changes of microRNAs in tissues is of great significance for the prevention and/or treatment of pathological changes and damage of tissues.
  • the present invention provides a method for inhibiting the function of miR-96 in protecting liver and muscle, and preventing and/or treating kidney disease and its complications, and relating to a decrease in total protein and/or albumin in blood. Use in diseases and symptoms as well as insulin resistance.
  • protecting the liver comprises: promoting liver synthesis of albumin and creatinine, preventing and/or treating liver function damage, hepatitis or cirrhosis.
  • protecting the muscle comprises: promoting muscle growth, preventing and/or treating muscle atrophy.
  • the diseases and conditions associated with decreased levels of total protein and/or albumin in the blood include hypoproteinemia, edema, ascites, and decreased renal function.
  • the kidney disease and its complications include: mesangial proliferative nephritis, diabetic nephropathy, edema caused by kidney disease or ascites, cerebral edema, brain damage, and elevated intracranial pressure caused by cerebral edema and brain damage.
  • the invention also provides for enhancing the function of miR-96 for enhancing lung function.
  • enhancing lung function comprises preventing and/or treating pulmonary function damage, pneumonia, emphysema or polyps.
  • the invention also provides a method of enhancing the function of miR-96, wherein the method comprises: contacting a miR-96 enhancer with a target cell expressing miR-96.
  • the invention also provides for the use of detecting the amount of miR-96 expressed in the blood in predicting whether the individual is at risk of developing liver disease, kidney disease and lung disease.
  • the present invention can fully inhibit the function of miR-96 by contacting a miR-96 inhibitor with a target cell expressing miR-96 (including inhibiting the binding of miR-96 to its target gene or reducing the expression level of miR-96, thereby inhibiting The function of miR-96), when used for individual administration, can effectively prevent and/or treat diseases caused by an increase in the amount of miR-96, for example, hypoproteinemia, liver function damage, muscle atrophy, insulin resistance And kidney disease.
  • diseases caused by an increase in the amount of miR-96 for example, hypoproteinemia, liver function damage, muscle atrophy, insulin resistance And kidney disease.
  • the function of miR-96 can be fully enhanced (including enhancing the binding of miR-96 to its target gene or increasing the expression of miR-96, thereby enhancing The function of miR-96, when used for individual administration, can effectively enhance lung function, for example, prevention and/or treatment of lung function damage, pneumonia, emphysema or polyps.
  • the amount of expression of miR-96 in the blood it is also possible to predict whether the individual is at risk of suffering from liver disease, kidney disease and lung disease.
  • Figure 1A is a linear plot of miR-96ASO dose versus its inhibitory effect on miR-96.
  • Figure 1B is a comparison of the functional effects of miR-96ASO, randomized control nucleotides, miR-96 mismatched ASO at the cellular level to inhibit miR-96.
  • Figure 2A shows the relationship between the amount of total protein (TP) in the blood of the experimental group db/db mice treated with the thio-modified miR-96ASO PJ150021 and the model group db/db mice.
  • Figure 2B shows the relationship between the arsenic-treated miR-96ASO PJ150021 treated experimental group db/db mice and albumin db/db mice blood albumin (ALB).
  • Figure 3 shows the relationship between thio-modified miR-96ASO PJ150021 treated experimental group db/db mice and creatinine (CRE) in the blood of model group db/db mice.
  • Figure 4A shows the kidney weight of db/db model group mice, normal control mice, and thio-modified miR-96ASO PJ150021 treated experimental group db/db mice.
  • Figure 4B shows the renal mesenteric lesions of the model group db/db mice, the negative control group db/db mice, and the thio-modified miR-96ASO PJ150021 treated experimental group db/db mice.
  • Figure 5 shows the enhancement of insulin sensitivity of thio-modified miR-96ASO PJ150021 treated db/db mice.
  • Figure 6 shows a comparison of the effect of miR-96 siRNA and randomized control siRNA on miR-96 expression.
  • miR-96 can regulate appetite and body weight, and db/db leptin receptor knockout mice regulated by negative feedback of appetite are used as a model [1], and in-depth study of miR-96 In function, it was found that inhibition of miR-96 can increase the total protein in the blood and the only albumin synthesized by the liver, while low levels of total protein and albumin cause hypoproteinemia, which in turn causes edema and ascites. It is well known that replenishing albumin can treat edema, ascites, cirrhosis and protect kidney function [2-3]. Inhibition of miR-96 also increases the amount of creatinine in the blood, but the amount of albumin in the urine does not increase.
  • Creatinine synthesis is mainly in the liver and kidney [4], thus indicating that inhibition of miR-96 function enhances the liver of db/db mice (eg, prevention and/or treatment of liver function damage, hepatitis or cirrhosis) and kidney The function. It is well known that creatinine mainly supplies muscle nutrition, can protect and promote muscle metabolism, and is often taken by athletes to enhance muscle strength [4-5]. In addition, the reduction of creatinine content is also related to convoluted atrophy, neurodegenerative diseases and muscular dystrophy. Related to diseases.
  • the kidney weight of db/db mice was positively correlated with the degree of renal damage. The heavier the kidney, the more severe the damage was [6]. The weight gain of the kidney is partly caused by the proliferation of mesangial cells [6]. Inhibition of miR-96 function also significantly inhibited the increase in kidney weight in db/db mice, and HE staining revealed that inhibition of miR-96 function inhibited proliferation of mesangial cells.
  • miR-96 Inhibition of miR-96 function reduces lung weight, suggesting that miR-96 functions to enhance lung function, while enhanced lung function can be used to prevent and/or treat lung function damage, pneumonia, emphysema or Multiple symptoms. miR-96 was detected from liver, muscle, lung and kidney of normal mice.
  • miR-96 is expressed in muscle, liver, lung and kidney, and subsequently demonstrated that liver and muscle can be protected by inhibiting the function of miR-96, and that low blood protein is prevented and/or treated.
  • inhibition of the function of miR-96 can increase the level of total protein in the blood and albumin synthesized by the liver (low levels of total protein and albumin cause hypoproteinemia, which in turn causes edema, ascites, and Reduced renal function; supplemental albumin can treat edema, ascites, cirrhosis, hepatitis, liver damage and protect kidney function), improve liver and kidney ability to synthesize creatinine (replenish muscle nutrition, protect muscles and promote muscle metabolism, prevention and prevention) / or treatment of convoluted atrophy, neurodegenerative diseases and muscular dystrophy), protect kidney function (inhibition of mesangial cells, prevention and treatment of kidney disease, especially diabetic nephropathy and edema caused by kidney disease or ascites, cerebral edema, brain Injury and increased intracranial pressure caused by cerebral edema and brain damage); while enhancing the function of miR-96 can enhance lung function (for prevention and/or treatment of lung function damage, pneumonia, emphy
  • the present invention provides for inhibiting the function of miR-96 in protecting the liver (promoting liver synthesis of albumin and creatinine, preventing and/or treating liver function damage, hepatitis or cirrhosis, preferably prevention and/or treatment associated with decreased creatinine content)
  • Diseases or symptoms such as convoluted atrophy, neurodegenerative diseases and muscular dystrophy) and muscle (promoting muscle growth, preventing and/or treating muscle atrophy), and preventing and/or treating kidney disease and its complications (mesenchymal hyperplasia) Nephritis, diabetic nephropathy, edema caused by kidney disease, ascites, cerebral edema, brain damage, and increased intracranial pressure caused by cerebral edema and brain damage), diseases associated with decreased total protein and/or albumin in the blood And the use of symptoms (hypoproteinemia, edema, ascites and decreased renal function) and insulin resistance.
  • diseases or symptoms such as convoluted atrophy, neurodegenerative diseases and muscular dystrophy) and muscle (promoting muscle
  • the function of miR-96 can be inhibited by administering a miR-96 inhibitor, for example, by oral or subcutaneous injection or intramuscular or intravenous administration.
  • miR-96 has the nucleotide sequence set forth in SEQ ID No: 1 (UUUGGCACUAGCACAUUUUUGCU).
  • the "inhibition of the function of miR-96” refers to the degree of down-regulation of miR-96 expression of its target gene in a target cell expressing miR-96 of the same species which is not treated by the method of the present invention,
  • the degree of down-regulation of miR-96 expression of its target gene by miR-96 in a target cell treated by the present invention is reduced by at least a factor of 0.5, and can generally be reduced by at least a factor of 1, such as Figures 1A and 1B.
  • the present invention provides a method of inhibiting miR-96 function in a target cell expressing miR-96 in vivo or in vitro.
  • inhibiting the function of miR-96 means that the expression level of a target gene regulated by miR-96 is increased by directly or indirectly acting on miR-96 with an agent. Methods include, but are not limited to, the following:
  • MiR-96 inhibitors include, but are not limited to, naturally occurring or synthetic small molecule compounds that act directly on miR-96 to increase the expression of a target gene regulated by miR-96, usually molecular weight.
  • candidate compounds possess functional groups that interact with proteins, particularly hydrogen bonds, and typically comprise at least one amine, carbonyl, hydroxyl or carboxyl group.
  • nucleotides and nucleotide analogs such as morpholino that bind to the miR-96 promoter and inhibit its promoter activity.
  • the antisense oligonucleotide can inhibit the function of the target miR-96 by direct binding to the target miR-96, and binds the antisense RNA and the antisense DNA.
  • the antisense oligonucleotide is complementary to miR-96, has a length of 8-30 nucleotides, and has a sequence complementary to nucleotides 2-8 of miR-96.
  • microRNAs can recognize and silence the expression and/or translation of a target gene by complementary pairing with a target gene.
  • miR-96 can also bind to a partially complementary core.
  • the nucleotide sequence competitively inhibits its own function, thereby upregulating the expression of the target gene of miR-96.
  • the term "complementary" includes not only complete complementarity but also partial complementarity.
  • the antisense oligonucleotide has the following nucleotide sequence:
  • the antisense oligonucleotide When in the case of incomplete complementation, that is, when the antisense oligonucleotide is deleted, substituted or added by one or several nucleotides in the nucleotide sequence shown in SEQ ID No:
  • the antisense oligonucleotide preferably has at least 60%, 65%, 70%, 75%, 80%, 85 with respect to miR-96 in the region of the complementary nucleotide. %, 90% or 95% complement each other. More preferably, the antisense oligonucleotide has a mismatch of up to 2 nucleotides in the nucleotide region 2-8 of miR-96.
  • the antisense oligonucleotide is not completely complementary to miR-96, it is further preferred that there are at most 10, 9 in length compared to SEQ ID No: 4. A difference of 8, 7, 6, 5, 3, 2 or 1 nucleotides.
  • the antisense oligonucleotide that is not fully complementary to miR-96 has the nucleotide sequence set forth in SEQ ID No: 5 (TAGTGAATTCTGCTAGTGCCATA).
  • the present invention also encompasses some conventional modifications of the antisense oligonucleotide to improve the stability and activity of the antisense oligonucleotide, all of which are within the scope of the invention.
  • RNA is DNA.
  • the antisense oligonucleotide is capable of being complementary (fully complementary or partially complementary) to miR-96, when the antisense oligonucleotide is contacted with a target cell expressing miR-96 in vivo or in vitro,
  • the antisense oligonucleotide is capable of complementary pairing with miR-96 and inhibits the binding of miR-96 to its target gene (ie, inhibits the activity of miR-96), thereby breaking the silence of miR-96 on its target gene.
  • the method comprises introducing an effective amount of an antisense oligonucleotide complementary to miR-96 into a target cell expressing miR-96.
  • the "effective amount” differs depending on the target cell expressing miR-96, and exhibits a certain dose effect, as shown in FIG. 1A of the present invention, according to conventional experimental means by those skilled in the art. And the intended purpose achieved can readily determine the effective dose for target cells expressing miR-96.
  • the antisense oligonucleotide of the present invention can be administered to an individual by conventional methods of nucleic acid administration.
  • administration of the antisense oligonucleotide can be carried out using the following method: the antisense oligonucleotide can be administered by a method of viral infection, microinjection, or vesicle fusion, or can also be passed A method of jet injection is used for muscle administration of the antisense oligonucleotide.
  • the antisense oligonucleotide may be applied to gold particles and then transdermally administered by a known method such as a particle bombardment apparatus or a "gene gun". These are all technical means conventional in the art, and the present invention will not be repeated here.
  • the antisense oligonucleotide can also be introduced into a target cell expressing miR-96 by an expression vector.
  • expression vectors have a restriction site located adjacent to the promoter sequence to facilitate insertion of the antisense oligonucleotide.
  • the transcription cassette located in the expression vector may include a transcription initiation region, a target gene or a fragment thereof, and a transcription termination region.
  • the vector can be, for example, but not limited to, a plasmid, a virus, etc., and can be selected by a person skilled in the art according to actual conditions.
  • antisense oligonucleotides can also be introduced into target cells expressing miR-96 by means of respiratory spray administration, for example by preparation into a spray formulation.
  • the antisense oligonucleotide may also be introduced into a target cell expressing miR-96 by oral administration, for example, by preparation into an oral preparation, or by the antisense The oligonucleotide is administered orally in a manner that is mixed with the food.
  • An individual as described above may be any mammalian cell, including but not limited to: ungulates, eg, cows, goats, pigs, sheep, etc.; rodents, eg, hamsters, mice, rats, rabbits; primates For example, monkeys, baboons, humans, etc.
  • the antisense oligonucleotide or a vector containing the antisense oligonucleotide can be directly added to The substrate in which the target cell expressing miR-96 is cultured is contacted, and the target cell expressing miR-96 into which the antisense oligonucleotide is introduced is cultured under conventional cell culture conditions.
  • the RNAi agent targets a precursor molecule of miR-96 (pre-microRNA, as shown in SEQ ID No: 2, UGGCCGAUUUUGGCACUAGCACAUUUUUGCUUGUGUCUCUCCGCUCUGAGCAA UCAUGUGCAGUGCCAAUAUGGGAAA), which modulates miR- via a mechanism of RNA interference Expression of 96, that is, indirectly inhibits the function of miR-96.
  • pre-microRNA as shown in SEQ ID No: 2, UGGCCGAUUUUGGCACUAGCACAUUUUUGCUUGUGUCUCUCCGCUCUGAGCAA UCAUGUGCAGUGCCAAUAUGGGAAA
  • RNA interference is a phenomenon in which homologous mRNA is efficiently and specifically degraded by double-stranded RNA (dsRNA). Since RNAi technology can specifically knock out or turn off the expression of specific genes, this technology has been widely used to explore the field of gene function and treatment of infectious diseases and malignant tumors.
  • the present application by using interfering RNA of the precursor molecule of miR-96, causes gene silencing of the precursor molecule of miR-96, thereby reducing the level of the precursor molecule of miR-96, thereby reducing The level of mature miR-96 converted from the precursor molecule of miR-96, that is, inhibits the function of miR-96, thereby increasing the expression level of the miR-96 target gene.
  • the RNAi agent can be a small RNA molecule, usually a single-stranded deoxyoligonucleotide (shRNA) that theoretically forms a small hairpin structure, typically no more than 100 nucleotides in length, typically No more than 75 nucleotides; or a 15-30 bp double-stranded deoxyoligonucleotide (siRNA), most typically 20-23 bp, as described in Example 5 of the present invention (eg SEQ)
  • the antisense strand represented by ID No: 7 and the sense strand as shown in SEQ ID No: 8.
  • the RNAi agent can also be a template DNA encoding shRNA or siRNA.
  • template DNA may be present in a vector, such as a plasmid vector or a viral vector; or may be absent from the vector, but a template DNA encoding shRNA or siRNA plus a common promoter sequence fragment that controls its transcription.
  • the contact of the RNAi agent with the target cell expressing miR-96 may also be in vivo contact or in vitro contact.
  • the method of administering the RNAi agent can be carried out with reference to the description of the antisense oligonucleotide as described above, and the present invention will not be described in detail herein in order to avoid unnecessary repetition.
  • the above miR-96 inhibitor can be administered in the form of a pharmaceutical composition comprising a miR-96 inhibitor as described above and a pharmaceutically acceptable carrier.
  • the content of the miR-96 inhibitor as described above as an active ingredient may vary within a wide range, and may be, for example, 0.000001 to 99%, preferably 1 to 70%. More preferably, it may be 5-30%.
  • the pharmaceutical composition can be prepared into various dosage forms conventional in the art, and the present invention is not particularly limited thereto, and for example, it can be formulated into a solid, semi-solid, liquid or gaseous form, for example, a tablet. , capsules, elixirs, suspensions, syrups, powders, granules, ointments, suppositories, injections, inhalants, aerosols, and the like, which are not enumerated herein.
  • various forms of administration may be carried out depending on the pharmaceutical dosage form, such as, but not limited to, oral administration, buccal administration, rectal administration, parenteral administration, intraperitoneal administration, and respiratory administration. , intradermal administration, transdermal administration.
  • the pharmaceutically acceptable carrier can be selected differently depending on the dosage form, which are well known to those skilled in the art.
  • the pharmaceutically acceptable carrier can be starch, gum, lactose, glucose, sucrose, microcrystalline cellulose, kaolin, mannitol, dibasic calcium phosphate, sodium chloride, alginic acid, and the like.
  • additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives may also be added.
  • the pharmaceutically acceptable carrier may further comprise a targeting agent capable of enhancing targeting of the antisense oligonucleotide to a particular organ or tissue or cell, such as a targeting peptide, and may also These include transmembrane agents that are capable of carrying the antisense oligonucleotides more readily into target cells expressing miR-96, such as transmembrane peptides, liposomes, microvesicles, and membrane lipoproteins.
  • a targeting agent capable of enhancing targeting of the antisense oligonucleotide to a particular organ or tissue or cell, such as a targeting peptide
  • transmembrane agents that are capable of carrying the antisense oligonucleotides more readily into target cells expressing miR-96, such as transmembrane peptides, liposomes, microvesicles, and membrane lipoproteins.
  • a flavoring agent such as peppermint, wintergreen oil or the like may be added to the pharmaceutical composition.
  • coloring agents may also be added to the pharmaceutical composition to impart a certain degree of attractiveness to the prepared dosage form or to distinguish it from other products.
  • the antisense oligonucleotide can also be combined with other conventional drugs capable of similar effects to prepare a combination pharmaceutical composition.
  • a combination pharmaceutical composition for example, it can be prepared in combination with a drug for inhibiting insulin resistance as a drug for effectively treating diabetes.
  • said use of the invention comprises the preparation of a medicament and/or food for the prevention and/or treatment of any of the above diseases and/or symptoms.
  • the food product comprises a health care product.
  • the treatment refers to an improvement or complete disappearance of a subject's symptoms associated with a disease or condition caused by miR-96, wherein a broad sense of improvement refers to a reduction of at least one parameter.
  • a broad sense of improvement refers to a reduction of at least one parameter.
  • the individual to be treated can be any individual, preferably a mammal, afflicted with the symptoms described above.
  • the invention also provides for enhancing the function of miR-96 for enhancing lung function (prevention and/or treatment of lung function damage, pneumonia, emphysema or polyps).
  • the invention also provides a method of enhancing the function of miR-96, wherein the method comprises: contacting a miR-96 enhancer with a target cell expressing miR-96.
  • the miR-96 enhancer comprises synthetic mature miR-96 (see sequence 1), a precursor of miR-96, an agonist of miR-96 (agomir), and transcription that positively regulates miR-96 Horizontal small molecule compounds, proteins, and nucleic acids and analogs thereof.
  • the administration form, the administration form, and the administration target of the enhancer can be set in the form of an inhibitor as described above, and will not be described in detail herein.
  • the present invention also provides for the use of detecting the expression level of miR-96 in blood in predicting whether an individual has a risk of suffering from liver disease, kidney disease and lung disease.
  • the miR-96 gene (GGTACAAAGACCTCCTCTGCTCCTTCCCCAGAGGGCCTGTT CCAGTACCATCTG CTTGGCCGATTGTGGCACTAGCACATTTTGGCTTGTGTCTCCGCTGTGAGCAATC ATGTGTAGTGCCAATATGGGAAAAGCGGGCTGCTGC GGCCACGTTCACCTCCCCCGGCATCC) shown in SEQ ID No: 3 was cloned into the pCAG-GFP vector to obtain the overexpression plasmid pCAG-miR-96-GFP of the miR-96 gene. Among them, the synthesis and cloning of the miR-96 gene shown by SEQ ID No: 3 was carried out by Kingsray.
  • miR-96 sensor vector miR-96sensor vector
  • the miR-96 receptor vector is a fire luciferase gene 3 cloned into the pGL3-SV40 vector by binding a confirmed miR-96 binding and regulatory target sequence (AAAGAAACCATCAAGTTGTGCCAAA) as shown in SEQ ID No:11. 'The downstream xbaI site was obtained, so that the expression of fire luciferase in the miR-96 receptor vector was regulated by miR-96.
  • This example is to illustrate the in vitro regulation of antisense oligonucleotides on miR-96
  • HEK-293T Human embryonic kidney cells HEK-293T were cultured in DMEM medium containing 10% fetal bovine serum. The cell culture incubator was constantly maintained at 37 ° C and 5% CO 2 . HEK-293T cells were seeded in a 24-well cell culture plate at a seeding rate of 100,000 cells per well at a culture volume of 500 ⁇ l. The following day, the settings of Table 1 below were co-transfected into KEK-293 cells using liposome 2000 (Invitrogen) according to the instructions, and expression from the miR-96 receptor vector was measured 36 hours later using a dual luciferase analyzer (Promega). The luciferase activity. Three replicate wells were set each time and the experiment was repeated three times.
  • the transgenic amount of miR-96 receptor vector in each group was 500 ng for miR-96 receptor vector, 20 ng for pCAG-GFP blank vector, 500 ng for miR-96 overexpression vector, and 50 ⁇ M for oligonucleotide.
  • the solution Further, when the transferred oligonucleotide was miR-96ASO, 0.5 ⁇ l and 1 ⁇ l of a 50 ⁇ M oligonucleotide solution were respectively added, and the final concentrations were 0.0417 ⁇ M and 0.0833 ⁇ M, respectively, after being added to the cell culture solution. To measure the activity of luciferase, and take the ordinate as the ordinate and the concentration of miR-96ASO as the abscissa, draw a curve. The results are shown in Figure 1.
  • miR-96ASO inhibits the function of miR-96.
  • the miR-96 receptor vector, miR-96 overexpression vector and different concentrations of miR-96ASO were co-transfected.
  • the luciferase activity assay showed that miR-96ASO can inhibit the function of miR-96, and Dose effect.
  • miR-96 in HEK293 cells inhibited the expression level of the reporter gene luciferase in the miR-9 receptor vector to 47% of the control group, while co-transforming the final concentration of 0.0833 ⁇ M of miR-96ASO, The expression of the reporter gene luciferase in the miR-96 receptor vector was restored to 76% of the control level, ie miR-96ASO was able to inhibit 54% of miR-96 function.
  • This example is intended to illustrate the antisense oligonucleotide of thio-modified miR-96 by oral gavage (thio-miR-96ASO: A S G S CAAAAATGTGCTAGTGCCA S A S A, modification site: the last two phosphoric acids at both ends
  • thio-miR-96ASO A S G S CAAAAATGTGCTAGTGCCA S A S A, modification site: the last two phosphoric acids at both ends
  • One of the oxygen atoms in the ester is replaced by sulfur
  • Leptin binds to the leptin receptor and activates the downstream signaling pathway, which inhibits the appetite of the individual.
  • the leptin receptor gene in db/db mice is mutated, so the leptin negative feedback in db/db mice impairs the appetite signaling pathway.
  • Continuous feeding makes db/db mice gain weight, liver and kidney weight increase, and affect liver and kidney function, leading to diabetic nephropathy [1,6].
  • the PJ150021 treatment group received 16 mg/kg of PJ150021 per day, and the negative control group received 16 mg/kg of negative control nucleic acid (SEQ ID No: 6) per day.
  • the model control group received an equal volume of normal saline per day. After 5 weeks of drug treatment, glucose was administered after 12 hours of fasting, and then changes in blood glucose concentration (glucose tolerance test, OGTT) and insulin injection 12 hours after the abdomen were measured continuously, and then changes in blood glucose concentration were continuously measured (insulin tolerance test).
  • ITT insulin receptor tetrachloride
  • blood sampling biochemical indicators including total protein, albumin and creatinine in the blood, dissecting organs and weighing, while HE staining of mouse mesangial cells for observation Its proliferation.
  • PJ150021 significantly increased the total protein (Fig. 2A) and albumin content (Fig. 2B) and creatinine content in the blood of db/db mice (Fig. 3).
  • PJ150021 significantly inhibited the increase in kidney weight in db/db mice (Fig. 4) and reduced proliferation of mesangial cells (Fig. 4B), reducing lung weight.
  • the insulin resistance test results demonstrated that PJ150021 significantly enhanced the sensitivity of db/db mice to insulin ( Figure 5).
  • siRNA small interfering RNA
  • HEK-293T Human embryonic kidney cells HEK-293T were cultured in DMEM medium containing 10% fetal bovine serum. 37 [deg.] C incubator and maintained constant 5% CO 2, the culture volume of 500 ⁇ l. The next day, miR-96 siRNA (antisense strand SEQ ID No: 7: 5'CUCAGAGCGGAGAGACACAAG'3, sense strand SEQ ID No: 8: 5'CUUGUGUCUCUCCGCUCUGAG'3, Shanghai Jima was prepared according to the instructions using liposome 2000 (Invitrogen).
  • miR-96 siRNA could down-regulate the expression of miR-96 by 70%, and thus the amount of miR-96 bound to the target gene of miR-96 was also down-regulated by 70%, thereby increasing the expression level of the target gene. It can be seen that the function of miR-96 can also be successfully inhibited by RNA interference with the miR-96 precursor.
  • the present invention can sufficiently inhibit miR-96 in a target cell expressing miR-96 by contacting a miR-96 inhibitor (including an antisense oligonucleotide and an interfering RNA) with a target cell expressing miR-96 in vivo or in vitro.
  • a miR-96 inhibitor including an antisense oligonucleotide and an interfering RNA
  • Function antisense oligonucleotide inhibits the binding of miR-96 to its target gene
  • interfering RNA can reduce the expression of miR-96, thereby inhibiting the function of miR-96
  • the disease caused by an increase in the amount of miR-96 is prevented and/or treated, for example, hypoproteinemia, edema, liver function damage, muscle atrophy, insulin resistance, and kidney disease. It provides a new direction for the treatment of diseases such as hypoproteinemia, edema, liver function damage, muscle atrophy, insulin resistance and kidney disease, and thus has extremely high social and economic benefits.
  • the miR-96 inhibitor which can reduce the weight of the lung, it can be inferred that the weight of the lung can be increased by using the miR-96 enhancer, thereby protecting the lung function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

L'invention concerne une application de l'inhibition de la fonction miR-96 dans la protection du foie et des muscles, dans la prévention et/ou le traitement de maladies rénales et de leurs complications et de maladies et symptômes liés à la diminution de la teneur en protéine totale et de la teneur en albumine dans le sang, et dans la résistance à l'insuline, une application de l'amélioration de la fonction miR-96 dans l'amélioration de la fonction pulmonaire, un procédé d'amélioration de la fonction miR-96, et une application de la détection du niveau d'expression de miR-96 dans le sang pour prédire si un individu risque de souffrir de maladies hépatiques, rénales et pulmonaires. En mettant un inhibiteur de miR-96 en contact avec une cellule cible exprimant miR-96, des maladies provoquées par l'augmentation de la quantité de miR-96 peuvent être efficacement évitées et/ou traitées ; en outre, un activateur de miR-96 peut augmenter le poids pulmonaire, et ainsi protéger la fonction pulmonaire.
PCT/CN2017/119889 2016-12-29 2017-12-29 Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l'insuline Ceased WO2018121743A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611242981.6 2016-12-29
CN201611242981.6A CN108261546A (zh) 2016-12-29 2016-12-29 miR-96用于保护肝、肌肉、肺和肾及调控血液总蛋白和白蛋白含量及胰岛素抵抗

Publications (1)

Publication Number Publication Date
WO2018121743A1 true WO2018121743A1 (fr) 2018-07-05

Family

ID=62706936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/119889 Ceased WO2018121743A1 (fr) 2016-12-29 2017-12-29 Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l'insuline

Country Status (2)

Country Link
CN (1) CN108261546A (fr)
WO (1) WO2018121743A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224983A (zh) * 2013-02-22 2013-07-31 上海大学 非小细胞肺癌中miR-96基因的应用
CN103476947A (zh) * 2011-03-02 2013-12-25 格路福生物制药公司 寡聚体的增强的生物分布
CN106267207A (zh) * 2015-06-05 2017-01-04 昆山彭济凯丰生物科技有限公司 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476947A (zh) * 2011-03-02 2013-12-25 格路福生物制药公司 寡聚体的增强的生物分布
CN103224983A (zh) * 2013-02-22 2013-07-31 上海大学 非小细胞肺癌中miR-96基因的应用
CN106267207A (zh) * 2015-06-05 2017-01-04 昆山彭济凯丰生物科技有限公司 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAO, L.D: "MicroRNA-185 Targets SOCS3 to Inhibit Beta- Cell Dysfunction in Diabetes", PLOS ONE, vol. 10, no. 2, 6 February 2015 (2015-02-06), pages 1 - 14, XP055511767, Retrieved from the Internet <URL:https://doi.org/10.1371/journal.pone.0116067> *
CHEN, X.M .: "MicroRNA signatures in liver diseases", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 15, no. 14, 14 April 2009 (2009-04-14), pages 1665 - 1672, XP055511779, Retrieved from the Internet <URL:DOI:10.3748/wjg.15.1665> *
HOUBAVIY, H.B ET AL.: "Embryonic Stem Cell -Specific MicroRNAs", DEVELOPMENTAL CELL, vol. 5, 31 August 2003 (2003-08-31), XP002540101 *
KIM, S.H: "Down-Regulation of miR-96 by Bone Morphogenetic Protein Signa- ling is Critical for Vascular Smooth Muscle Cell Phenotype Modulation", J CELL BIOCHEM, vol. 115, no. 5, 31 May 2014 (2014-05-31), XP002737077 *

Also Published As

Publication number Publication date
CN108261546A (zh) 2018-07-10

Similar Documents

Publication Publication Date Title
Zhang et al. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy
KR101697482B1 (ko) 진단 및 치료 목적을 위한 마이크로ｒｎａ 및 다운스트림 타겟
WO2012136859A1 (fr) Médicament pour régénérescence du foie et traitement d&#39;insuffisance hépatique
Xu et al. The microRNA miR-17 regulates lung FoxA1 expression during lipopolysaccharide-induced acute lung injury
Yang et al. Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo
Wang et al. TGF-β1/Smad3 signaling promotes collagen synthesis in pulmonary artery smooth muscle by down-regulating miR-29b
Ma et al. Cardiac over-expression of microRNA-1 induces impairment of cognition in mice
US20180193374A1 (en) Micro-rna for the treatment of malignant solid tumors and metastasis
US20120059159A1 (en) Differentiation therapy for sarcomas
WO2016192669A1 (fr) Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l&#39;intermédiaire de mir-96, et utilisation associée
CN116814620A (zh) 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途
US20160244755A1 (en) Treating diseases associated with pgc1-alpha by modulating micrornas mir-130a and mir-130b
TW202342747A (zh) 具有高穩定性和基因沉默活性的小干擾rna分子的修飾模式
WO2013174692A1 (fr) Cibles thérapeutiques micro arn dans des maladies pulmonaires chroniques
US8247389B2 (en) Treatment of scleroderma
WO2018210259A1 (fr) Médicament permettant de réguler l&#39;appétit et le poids corporel, et application associée
JP5850702B2 (ja) 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
WO2017084610A1 (fr) Application de mir-183 ou d&#39;un inhibiteur de celui-ci
WO2018121743A1 (fr) Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l&#39;insuline
CN108245527B (zh) 通过miR-1181进行抗癌的方法和药物及其应用
CN106581676B (zh) 癌症标志物、治疗癌症的药物组分及用途
US20230304007A1 (en) Compositions and methods of treatment of muscle disorders by targeting h19x-encoded non-coding rnas
WO2013113032A1 (fr) Le récepteur purinergique couplé à la protéine g gpr17 médie les effets oréxigènes de fox01 dans les neurones agrp
US20250163420A1 (en) Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128
KR101928427B1 (ko) 마이크로rna-497을 유효성분으로 포함하는 알코올성 간질환의 예방 또는 치료용 조성물 및 이의 스크리닝 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17887769

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17887769

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17887769

Country of ref document: EP

Kind code of ref document: A1